Clinical trial
Effects of Exenatide Long-Acting Release on Glucose Control and Safety in…
NCT00308139 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00308139 |
|---|---|
| Title | Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1) |
| Official title | A Randomized, Open-Label, Multicenter, Comparator-Controlled Study to Examine the Effects of Exenatide Long-Acting Release on Glucose Control (HbA1c) and Safety in Subjects With Type 2 Diabetes Mellitus Managed With Diet Modification and Exercise and/or Oral Antidiabetic Medications |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | exenatide, long acting release |
| Enrollment | 303 |
| Start date | Apr 1, 2006 |
| Primary completion | Jul 1, 2008 |
| Completion | Aug 1, 2014 |
| First posted | Mar 29, 2006 |
| Last update posted | Aug 26, 2015 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: